402 related articles for article (PubMed ID: 36648882)
1. Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again.
Plano F; Corsale AM; Gigliotta E; Camarda G; Vullo C; Di Simone M; Shekarkar Azgomi M; Speciale M; Carlisi M; Caccamo N; Dieli F; Meraviglia S; Siragusa S; Botta C
Hematol Rep; 2023 Jan; 15(1):23-49. PubMed ID: 36648882
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities.
Botta C; Mendicino F; Martino EA; Vigna E; Ronchetti D; Correale P; Morabito F; Neri A; Gentile M
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34203150
[TBL] [Abstract][Full Text] [Related]
3. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
Ho M; Patel A; Goh CY; Moscvin M; Zhang L; Bianchi G
Leukemia; 2020 Dec; 34(12):3111-3125. PubMed ID: 33046818
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
5. PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients.
Costa F; Vescovini R; Marchica V; Storti P; Notarfranchi L; Dalla Palma B; Toscani D; Burroughs-Garcia J; Catarozzo MT; Sammarelli G; Giuliani N
Front Immunol; 2020; 11():613007. PubMed ID: 33488620
[TBL] [Abstract][Full Text] [Related]
6. Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma.
Calcinotto A; Ponzoni M; Ria R; Grioni M; Cattaneo E; Villa I; Sabrina Bertilaccio MT; Chesi M; Rubinacci A; Tonon G; Bergsagel PL; Vacca A; Bellone M
Oncoimmunology; 2015 Jun; 4(6):e1008850. PubMed ID: 26155424
[TBL] [Abstract][Full Text] [Related]
7. The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression.
García-Ortiz A; Rodríguez-García Y; Encinas J; Maroto-Martín E; Castellano E; Teixidó J; Martínez-López J
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33435306
[TBL] [Abstract][Full Text] [Related]
8. Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back.
Bianchi G; Anderson KC
CA Cancer J Clin; 2014; 64(6):422-44. PubMed ID: 25266555
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
[TBL] [Abstract][Full Text] [Related]
10. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease.
Isola I; Brasó-Maristany F; Moreno DF; Mena MP; Oliver-Calders A; Paré L; Rodríguez-Lobato LG; Martin-Antonio B; Cibeira MT; Bladé J; Rosiñol L; Prat A; Lozano E; Fernández de Larrea C
Front Immunol; 2021; 12():792609. PubMed ID: 34880879
[TBL] [Abstract][Full Text] [Related]
11. Monocyte Subsets and Serum Inflammatory and Bone-Associated Markers in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma.
Damasceno D; Almeida J; Teodosio C; Sanoja-Flores L; Mayado A; Pérez-Pons A; Puig N; Arana P; Paiva B; Solano F; Romero A; Matarraz S; van den Bossche WBL; Flores-Montero J; Durie B; van Dongen JJM; Orfao A
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33810169
[TBL] [Abstract][Full Text] [Related]
12. Is It Possible to Predict Tumor Progression Through Genomic Characterization of Monoclonal Gammopathy and Smoldering Multiple Myeloma?
Testa U; Leone G; Pelosi E; Castelli G; De Stefano V
Mediterr J Hematol Infect Dis; 2024; 16(1):e2024044. PubMed ID: 38882455
[TBL] [Abstract][Full Text] [Related]
13. Ferritin Metabolism Reflects Multiple Myeloma Microenvironment and Predicts Patient Outcome.
Plano F; Gigliotta E; Corsale AM; Azgomi MS; Santonocito C; Ingrascì M; Di Carlo L; Augello AE; Speciale M; Vullo C; Rotolo C; Camarda GM; Caccamo N; Meraviglia S; Dieli F; Siragusa S; Botta C
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240197
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).
Viera S; Ludek P; Zdeněk A; Marta K; Martin Š; Sabina Š; Zdeněk K
Klin Onkol; 2018; 31(4):270-276. PubMed ID: 30541309
[TBL] [Abstract][Full Text] [Related]
15. High Dimensional Immune Profiling of Smoldering Multiple Myeloma Distinguishes Distinct Tumor Microenvironments.
Fernandez N; Perumal D; Rahman A; Kim-Schulze S; Yesil J; Auclair D; Adams H; Parekh S; Gnjatic S; Cho HJ
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):853-862. PubMed ID: 35945129
[TBL] [Abstract][Full Text] [Related]
16. Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance.
Bladé J; Rosiñol L
Curr Treat Options Oncol; 2006 May; 7(3):237-45. PubMed ID: 16615879
[TBL] [Abstract][Full Text] [Related]
17. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
Mateos MV; Landgren O
Cancer Treat Res; 2016; 169():3-12. PubMed ID: 27696254
[TBL] [Abstract][Full Text] [Related]
18. [Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].
Adam Z; Krejčí M; Pour L; Sevčíková E; Křivanová A; Rehák Z; Koukalová R; Cermáková Z; Vaníček J; Sevčíková S
Vnitr Lek; 2014 Oct; 60(10):861-79. PubMed ID: 25382009
[TBL] [Abstract][Full Text] [Related]
19. Bone Tumors: Multiple Myeloma.
Kane SF
FP Essent; 2020 Jun; 493():30-35. PubMed ID: 32573185
[TBL] [Abstract][Full Text] [Related]
20. Multiple Myeloma: Molecular Pathogenesis and Disease Evolution.
Heider M; Nickel K; Högner M; Bassermann F
Oncol Res Treat; 2021; 44(12):672-681. PubMed ID: 34749378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
